Russell Investments Group Ltd. Purchases 26,506 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Russell Investments Group Ltd. increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 323.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 34,706 shares of the biopharmaceutical company’s stock after purchasing an additional 26,506 shares during the period. Russell Investments Group Ltd.’s holdings in TG Therapeutics were worth $1,045,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its position in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp increased its holdings in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at about $75,000. Finally, GAMMA Investing LLC lifted its stake in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

TGTX opened at $36.97 on Tuesday. The firm has a market cap of $5.81 billion, a P/E ratio of -369.66 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The business’s fifty day moving average is $36.46 and its 200-day moving average is $32.09.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.